



Uterine Cancer

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	4
Molecular Classification	4
Medicare Screenings (older adults, at-risk population)	5
Subtle Early Signs in Older Adults	6
Geriatric Risk Factors	6
Diagnostic Thresholds	7
Common Oversights	8
Key Differentials in Elderly	8
Comorbidity Screening	9
Staging/Severity Matrix	10
3. MEAT DOCUMENTATION ESSENTIALS	11
Clinical Documentation Elements	12
Reframing Common Documentation Shortcuts	12
4. TREATMENT AND REFERRAL QUICK GUIDE	13
NCCN Aligned Recommendations	14
Non-Pharmacologic Treatment and Lifestyle Modification	15
Non-Pharmaceutical Prevention Strategies	15
Medication Safety and Dose Adjustments	16
When to Refer	16
Follow-Up Timing	17
Comorbidity Management	17
Cost-Smart Options	18
5. CODING REMINDERS AND CASE EXAMPLES	19
Documentation Specificity	19
Annual Clinical Review and Confirmation	20
Good Documentation is Comprehensive Coding	20
Brief Case Examples	21
REFERENCES	22

1 CLINICAL SNAPSHOT

Definition: Malignant neoplasm of the uterine corpus — endometrial carcinoma accounts for ~95% of cases,¹ with endometrioid adenocarcinoma the dominant histology; serous, clear cell, and carcinosarcoma represent aggressive non-endometrioid subtypes. Molecular classification (POLE-mutated, MMR-deficient, NSMP, p53-abnormal) increasingly drives prognosis and treatment selection. Cardinal symptom is abnormal vaginal bleeding, present in >90% of postmenopausal¹ patients.

ICD-10 Codes: Primary corpus **C54.0** isthmus/**C54.1** endometrium/**C54.2** myometrium/**C54.3** fundus/**C54.8** overlapping/**C54.9** corpus unspecified (avoid); **C55** uterus part unspecified (avoid — most common upcoding error). Cervical cancer **C53.x** is a distinct family — never substitute. Metastatic: **C77.5** pelvic lymph nodes, **C79.82** secondary genital organs (HCC 18); **C78.6** peritoneum, **C78.7** liver, **C78.0x** lung (HCC 17). Code each metastatic site individually.

Prevalence: ACS projects ~68,270 new diagnoses² and ~14,450 deaths² in the U.S. in 2026 — the most common gynecologic cancer and the fourth most common cancer in women overall, with **incidence and mortality rising ~2% annually²** since the mid-2000s. Median age at diagnosis ~60 years;¹ ~80% diagnosed in postmenopausal women. ~67-70% diagnosed at Stage I; 5-year relative survival: Stage I 95-96%, Stage II 75%, Stage III >41%, Stage IV 17-22%; overall ~81-82%.^{1,3}

HCC/RAF V28 Mapping

ICD-10 CODE ¹⁻³	HCC CATEGORY	RAF WEIGHT	DOCUMENTATION REQUIREMENT
C54.x C54.1, C54.0, C54.2, C54.3, C54.8, C54.9, C55	HCC 23 — Prostate/Breast/and Other Cancers and Tumors	0.186	Active uterine cancer ; document histologic type (endometrioid, serous, clear cell, carcinosarcoma), grade , and FIGO stage . C54.1 is the default for endometrial origin; C55 should be used only when site is genuinely indeterminate

ABBREVIATIONS: ICD-10-CM = International Classification of Diseases, 10th Revision, Clinical Modification | HCC = Hierarchical Condition Category | RAF = Risk Adjustment Factor | CNA = Community Non-Dual Eligible, Aged | FIGO = International Federation of Gynecology and Obstetrics

RAF values represent the Community Non-Dual Eligible Aged (CNA) coefficient from the 2026 CMS-HCC model; values vary across patient populations based on eligibility and care setting

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time